Janet Robertson
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Cutaneous Melanoma Detection and Management, Ovarian cancer diagnosis and treatment, DNA Repair Mechanisms, HER2/EGFR in Cancer Research
Most-Cited Works
- → Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells(2019)50 cited
- → Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib(2020)49 cited
- → Synthetic Lethality Triggered by Combining Olaparib with BRCA2–Rad51 Disruptors(2017)40 cited
- → Requirements analysts must also be inventors(2005)38 cited
- → 435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes(2015)25 cited
- → Subaqueous Disposal of Reactive Mine Waste: An Overview and Update of Case Studies - MEND/CANADA(1994)23 cited
- → NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer(2016)14 cited
- → NICE guidance on ipilimumab for treating previously untreated advanced (unresectable or metastatic) melanoma(2014)13 cited
- → NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma(2014)10 cited
- → NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer(2013)10 cited